REVCO AUTHORIZING CMTE. TO IMPROVE CHAIN's PURCHASING PROCEDURES
REVCO AUTHORIZING CMTE. TO IMPROVE CHAIN's PURCHASING PROCEDURES, the company stated in a Sept. 7 press release.Revco said a special cmte. of outside directors, which was appointed in July to investigate allegations about the chain's purchasing practices, has been authorized by the board to "continue to work with management consultants from Peat, Marwick, Mitchell & Co. in developing a program for continuing improvement in purchasing department procedures and policies and closer coordination with other departments." Revco's board also approved plans proposed by VP-merchandising and purchasing Daniel Horowitz for purchasing improvements. The cmte. found that there had been "inadequate procedures and practices within the purchasing department" which "contributed to some purchasing mistakes," the release said. The group also identified a "lack of coordination between the purchasing of promotional goods and regular inventory, scheduling difficulties for promotional items with related advertising circulars, weakness in verification of certain purchase order quantities with quantities actually delivered, timing of deliveries for some seasonal goods, and coordination among purchasing, store operations and warehouses." The cmte. concluded, however, that the "specific allegations" made by Odd Lot subsidiary officials Isaac Perlmutter and Bernard Marden were "in many cases insignificant, contained extensive errors factually, and in large part dealt with matters where business judgment could have gone either way at the time the decision was made." None of the allegations have had "a material financial (BRACKET)effect(BRACKET) on the company," the cmte. said. The board approved the transfer of purchasing responsibility from Elliot Dworkin, now VP-marketing, to Horowitz. Revco merged merchandising and purchasing responsibilities under Horowitz in August. The board also approved Revco's decision to terminate further purchasing through Joseph DeKama.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth